62 studies found for:    burzynski
Show Display Options
RSS Create an RSS feed from your search for:
burzynski
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Antineoplaston Therapy in Treating Patients With Residual or Recurrent Anaplastic Astrocytoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
2 Unknown  Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer
Condition: Adrenocortical Carcinoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
3 Unknown  Antineoplaston Therapy in Treating Patients With Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
4 Unknown  Antineoplaston Therapy in Treating Children With Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
5 Unknown  Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
6 Unknown  Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
7 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
8 Unknown  Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
9 Unknown  Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
10 Unknown  Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
11 Unknown  Antineoplaston Therapy in Treating Patients With Refractory or Recurrent Intermediate-Grade Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
12 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory High-Grade Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
13 Withdrawn Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma
Conditions: Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
14 Withdrawn Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Condition: Primary Central Nervous System Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
15 Terminated Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Condition: Malignant Mesothelioma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
16 Completed Antineoplaston Therapy in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
17 Unknown  Antineoplaston Therapy in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
18 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
Conditions: Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
19 Unknown  Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
20 Withdrawn Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
Conditions: Merkel Cell Carcinoma;   Islet Cell Carcinoma;   Neuroendocrine Carcinoma;   Pituitary Tumor
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years